ArticleBiotechnology letters2025
Advancing Yarrowia lipolytica sub-organelle engineering with endogenous mitochondrial targeting sequence.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThe aim of the study was identification and validation of an endogenous mitochondrial targeting signal (MTS) sequence of Yarrowia lipolytica, for efficient compartmentalization of a target protein to mitochondria.
resultsMTS from citrate synthase of Y. lipolytica (YlCISY-MTS) was identified, isolated and fused with green fluorescent protein (GFP) to direct it to the mitochondrial matrix. The efficiency of localization of GFP to mitochondrial matrix with YlCISY-MTS was compared with currently used MTS from Saccharomyces cerevisiae's cytochrome oxidase subunit IV. Confocal microscopy confirmed the targeted and greater GFP localization, underlining the potential of endogenous YlCISY-MTS for mitochondrial engineering in Y. lipolytica. The availability of endogenous MTS will evade the need of codon optimization of S. cerevisiae MTS for mitochondrial engineering in Y. lipolytica. This is the first report of an endogenous MTS of Y. lipolytica.
conclusionAn endogenous MTS of Y. lipolytica has been identified to facilitate the targeted delivery of a protein in the mitochondria enabling future advancements through leveraging the unique subcellular environment for metabolic engineering applications.
Indexed as
Identifiers
40338364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.